TITLE: ANTIBODY-DRUG CONJUGATE

ABSTRACT

A use of a novel anti-CDCP-1 antibody or an antigen-binding fragment thereof, a linker compound, a deuterated payload, and a linker-payload compound in an antibody-drug conjugate, specifically relating to an anti-CDCP-1 antibody having good cell binding activity and affinity, and a linker and a payload compound that exhibit potent cytotoxicity and significant inhibitory activity on tumor cells. The antibody-drug conjugate prepared by using the anti-CDCP-1 antibody, the linker, and the payload compound can produce good inhibitory activity on tumors in vitro and in vivo, and has good safety. The described advantages are of great value for the development of the antibody-drug conjugate in clinical treatment.

(FIG. 1)